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Primary hyperoxaluria type 1 results from alanine:glyoxylate
aminotransferase deficiency. Due to genotype/phenotype
heterogeneity in this autosomal recessive disorder, the renal
outcome is difficult to predict in these patients and the long-
term impact of conservative management in children is
unknown. We report here a multicenter retrospective study on
the renal outcome in 27 affected children whose biological
diagnosis was based on either decreased enzyme activity or
identification of mutations in the patient or his siblings. The
median age at first symptoms was 2.4 years while that at
initiation of conservative treatment was 4.1 years; 6 children
were diagnosed upon family screening. The median follow-up
was 8.7 years. At diagnosis, 15 patients had an estimated
glomerular filtration rate (eGFR) below 90, and 7 children
already had stage 2–3 chronic kidney disease. The median
baseline eGFR was 74, which rose to 114 with management in
the 22 patients who did not require renal replacement therapy.
Overall, 20 patients had a stable eGFR, however, 7 exhibited a
decline in eGFR of over 20 during the study period. In a Cox
regression model, the only variable significantly associated with
deterioration of renal function was therapeutic delay with a
relative risk of 1.7 per year. Our study strongly suggests that
early and aggressive conservative management may preserve
renal function of compliant children with this disorder, thereby
avoiding dialysis and postponing transplantation.
Kidney International (2009) 76, 767–773; doi:10.1038/ki.2009.237;
published online 1 July 2009
KEYWORDS: orphan disease; primary hyperoxaluria type 1; renal insuffi-
ciency; survival
Type 1 primary hyperoxaluria (PH1) is an autosomal
recessive disorder caused by a deficit in the liver-specific,
peroxisomal, alanine:glyoxylate aminotransferase (AGT).
AGT deficiency leads to overproduction of oxalate and
deposition of insoluble calcium oxalate crystals in tissues.1,2
More than 100 mutations have been identified on AGXT, the
gene encoding AGT,3 few being frequent. To this genetic
heterogeneity is added a marked phenotypic heterogeneity,
and genotype/phenotype correlations have yet to be clearly
demonstrated.4 Pyridoxine is the AGT co-factor and B6
sensitivity has been shown in 10–30% of patients, especially
in those with the G170R mutation.5,6
Calcium oxalate deposition in tissues eventually leads
to renal failure and oxalosis, a multiorgan involvement.
End-stage renal disease (ESRD) is reached between 25 and
33 years of age in 50% of cases,7–9 whereas first symptoms
appear at a median age of 5–6 years. Conservative measures
are based on the reduction of calcium oxalate precipitation
by high fluid intake (2–3 l/m2/day), urine alkalinization,
and crystallization inhibitors such as citrate, bicarbonate,
and magnesium.10–12 Treatment with pyridoxine can poten-
tially reduce oxalate production in B6-sensitive patients.13,14
Conventional dialysis does not permit sufficient oxalate
removal as production rates exceed clearance capacity.15–17
Liver transplantation is currently the only acceptable option
and is mostly performed as combined or sequential
liver–kidney transplantation when ESRD has been, or is soon
to be, reached.18,19 Although the individual course of the
disease is unpredictable, conservative treatment started at the
time of diagnosis while renal function was still good, might
be able to delay further renal deterioration. This is of
particular interest in children with early diagnosis, as in
family screening.
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The purpose of this study is to describe the renal out-
come of patients on conservative treatment in a pediatric
population.
RESULTS
Population characteristics
The diagnosis database included 40 childreno15 years of age;
13 patients were excluded because of ESRD at presentation
(n¼ 10, with six patients with infantile PH1), pre-emptive
liver transplantation (n¼ 1), follow-upo1 year (n¼ 1), and
unavailable data (n¼ 1). Thus, 27 children aged less than 15
years at treatment initiation were included for analysis.
Among the 27 patients (sex ratio 0.48), 11 were western
Europeans and 14 were Mediterraneans. Consanguinity was
reported in 13. A positive family history of PH1 or lithiasis
was found in 12. The diagnosis was made on family screening
in six children.
Clinical presentation
The median age at first symptom was 29 months (0.5–94.0),
and was before 5 years of age in 22/27 patients (Table 1).
Median age at diagnosis was 49 months (0.9–148), with a
median therapeutic delay of 7.5 months (0–108). Three
children were diagnosed before any renal symptom had
occurred, as family screening, and four children were
diagnosed within 2 months of first symptoms. Fifteen
children had renal function impairment at diagnosis, and
one child presented with extrarenal (bone) involvement.
Diagnosis of PH1
Diagnosis of PH1 was based on enzymatic deficiency on
hepatic biopsy in 16/27 patients with a median corrected
enzymatic activity of 0.5 mmol pyruvate/sec per kg protein
(0–18) (normal values: 490–750). Mutation screening was
carried out for 25/27 patients and at least one AGXT
mutation identified for all patients. The c.731T4C (I244T)
mutation was found in 7/25 patients of Mediterranean
descent, 6 homozygous and 1 heterozygous, representing
26% of alleles searched. The c.508G4A (G170R) mutation
was found in 4/25, as a heterozygous mutation (8% of
alleles). Other mutations found included 33–34 insC (12% of
patients; 8% of alleles), c.568G4A (G190R, 12 and 8%,
respectively), c.584T4G (M195R, 8% for both), c.847-
1G4C (16 and 8%, respectively), c.847-3C4G (8 and 6%,
respectively), and private mutations for the rest. Only one
mutation could be identified for one patient.
Treatment
All patients received fluid intake orally (20/27) or enterally,
with nasogastric tube or gastrostomy (7/27) (Table 2). Fluid
intake ranged between 2 and 3 l/m2 per day for 8 children and
was over 3 l/m2 per day for 13 children. Most children also
received urine alkalinization, though two did not (one in
each group). Alkalinization consisted of sodium or potas-
sium citrate in 14, sodium bicarbonate in 7, and both citrate
and bicarbonate in 4. Magnesium was added for 13 children.
Sensitivity to pyridoxine was assessed in some patients but
formal testing could not be recorded in all. Seventeen
children were still treated with B6, 10 having been declared
B6 resistant after a median time of treatment of 6.6 years
(range 3.5–19). Mean B6 dose ranged between 10 and 20mg/
kg/day and was over 20mg/kg/day in two patients of group 2.
Renal outcome
Median follow-up was 8.7 years (1.8–18.8), with a median age
at last follow-up of 12.1 years (4.6–21.2) (Table 3). One
patient died during follow-up from a domestic accident.
Twenty-five children presented at least one nephrolithiasis
during follow-up, with a mean number of renal stone passage
of 2.1±0.5 (range 0–7) that required a mean number of
shock wave lithotripsy or open surgery of 1.5±0.4 (range
0–8). Nephrocalcinosis was found in 19 patients. Radiological
lesions were stable over time in 13 patients, diminished
or disappeared in 8, grew or appeared in 3, with data
unavailable in 3. Only one patient remained symptom-free
during follow-up. Median serum creatinine at the start of the
treatment was 52 mmol/l (29–115) and 66 mmol/l (33–246) at
the last follow-up. Median glomerular filtration rate (GFR)
was 74ml/min per 1.73m2 (29–141) at the start of the
treatment and 105ml/min per 1.73m2 at the last follow-up
(7–195); 85 (29–141) and 114 (40–195), respectively, when
patients with renal replacement therapy (RRT) later on are
excluded. Median DGFR was þ 11ml/min per 1.73m2 (86
to þ 124), þ 12 (40, þ 124) RRTexcluded (Figure 1), with
a median slope of þ 1.2ml/min per 1.73m2 per year. Of the
15 patients who presented with a decreased GFR at diagnosis
(GFRo90ml/min per 1.73m2), 7 already had chronic kidney
disease (CKD), as opposed to transiently decreased initial
GFR: 6 with stage 2 and 1 with stage 3. Three additional
patients reached CKD stage 2–4 later (Figures 1 and 2).
Survival-free from CKD stage 3 was 92% at 3 years of follow-
up, 78% at 5 years of follow-up (Figure 3a), with an overall
prevalence of CKD stage 2–4 of 37% (10/27 children). The
median time interval between start of the treatment and CKD
stage 3 was 4.1 years (2–9.9). CKD stage 2 occurred at a
median chronological age of 13.1 years (9–15.2). Four
patients reached ESRD and were treated by hemodialysis at
a median age of 17.8 years (15.3–21.3), with a GFR between 7
and 19ml/min per 1.73m2. Another patient was transplanted
pre-emptively at 15.1 years with a GFR of 19ml/min per
1.73m2 (Figure 2).
Among the five patients who required RRT, four were
transplanted at a median age of 18.3 years (15.1–22.1). One
patient received an isolated kidney graft and presented with
recurrence 4 months post-transplantation, leading to com-
bined liver–kidney transplantation with good results. Com-
bined liver–kidney transplantation was performed in the
other three patients, with kidney graft failure in one,
requiring a second kidney transplant 2 months later. The
median time interval between the start of the treatment and
RRTwas 9.6 years (7.1–11), RRToccurring at a median age of
16.2 (14.3–21.2) years. Survival-free from RRT (Figure 3b)
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after treatment initiation was 100% at 1 and 7 years and 80%
at 10 years (N¼ 8 children at risk at 10 years). The overall
prevalence rate of RRT was 19% (5/27). At 15 years of age,
100% of the children were free from RRT and 73% at
18 years.
Determinants in the evolution of renal function
According to renal outcome, patients were divided into two
groups: group 1 (favorable outcome) included 20 (74%)
patients and group 2 (unfavorable outcome that is, decline in
GFR420ml/min per 1.73m2) included 7 (26%) patients.
Table 1 | Baseline characteristics of 27 PH1 patients
Variable Total (n=27) Group 1 (n=20) Group 2 (n=7) P-value
Male, % 48 60 14.3 0.08
Ethnic origin, n (%) 0.81
Western European 11 (41) 7 (35) 4 (57)
Mediterranean 14 (52) 11 (55) 3 (43)
Other 2 (7) 2 (10) 0
Consanguinity, n (%) 13 (48) 10 (50) 3 (43) 1.00
Family history, n (%) 12 (44) 9 (45) 3 (43) 1.00
Presentation
Age at first symptoms, years (range) 2.4 (0.04–7.8) 1.8 (0.04–7.8) 4.0 (1.5–5.6) 0.21
GFRo90ml/min per 1.73m2, n (%) 15 (55) 10 (50) 5 (71) 0.39
CKD at diagnosis, n (%) 7 (26) 2 (10) 5 (71) 0.03
Nephrolithiasis, n (%) 25 (92) 18 (90) 7 (100) 1.00
Nephrocalcinosis, n (%) 19 (70) 12 (60) 7 (100) 0.07
Extrarenal involvement, n (%) 1 (4) 0 1 (14) 1.00
Diagnosis
Age at diagnosis, years (range) 4.1 (0.1–12.3) 2.8 (0.1–9.5) 8.0 (2.3–12.3) 0.02
Therapeutic delay, years (range) 0.6 (0.2–9.0) 0.1 (0.2–8.4) 2.4 (0.1–9.0) 0.02
Family screening, n (%) 6 (22) 5 (25) 1 (14) 1.00
Mutation, n (total n=25) (total n=19) (total n=6) 1.00
I244T 7 (28) 6 (32) 1 (17) 0.63
G170R 4 (16) 3 (16) 1 (17) 1.00
Other 14 (56) 10 (52) 4 (66)
AGT enzymatic activity, n=16 (mmol pyruvate/sec per kg protein) 0.5 (0–18) 0.1 (0–1.6) 0 (0–0.3) 0.18
AGT, alanine:glyoxylate aminotransferase (normal range: 490–750 mmol pyruvate/sec per kg protein);
CKD, chronic kidney disease; GFR, glomerular filtration rate; PH1, primary hyperoxaluria type 1.
Results are given as median and range when not otherwise specified.
Table 2 | Details of conservative treatment
Variable Total (n=27) Group 1 (n=20) Group 2 (n=7) P-value
Vitamin B6 treatment, n (%) 17 (63) 12 (60) 5 (71) 0.67
Vitamin B6 dose, n (%)
o10mg/kg/day 2 (7) 1 (5) 1 (14)
10–20mg/kg/day 10 (37) 9 (45) 1 (14)
420mg/kg/day 2 (7) 0 2 (29)
Unavailable 3 (11) 2 (10) 1 (14)
Type of hyperhydration, n (%) 1.00
Oral 20 (74) 15 (75) 5 (71)
Enteral 7 (26) 5 (25) 2 (29)
Fluid intake, n (%) 0.63
2–3 l/m2/day 8 (30) 5 (25) 3 (43)
43 l/m2/day 13 (48) 10 (50) 3 (43)
Unavailable 6 (22) 5 (25) 1 (14)
Alkalinization, n (%) 0.30
None 2 (7) 1 (5) 1 (14)
Citrate (Na or K) 14 (58) 12 (60) 2 (29)
Bicarbonate (Na) 7 (26) 5 (25) 2 (29)
Citrate+Na bicarbonate 4 (15) 2 (10) 2 (29)
Magnesium, n (%) 13 (48) 11 (55) 2 (29) 0.38
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There was no statistical difference between the two groups in
terms of sex ratio, ethnic background, consanguinity, family
history, diagnosis circumstances, mutations (frequencies of
I244T and G170R alleles), enzymatic activity, age at onset,
number of renal stone migration, nephrocalcinosis, radio-
logical evolution, initial GFR, treatment modalities (B6 dose,
hyperhydration, alkalinization, and use of crystalliza-
tion inhibitors), and duration of follow-up (Tables 1–3).
In univariate analysis (Table 2), patients in group 2 were
statistically older at diagnosis (94±18 vs 45±8 months in
group 1; P¼ 0.025), had a longer therapeutic delay between
first symptoms and treatment initiation (51±19 vs 13±6
months in group 1; P¼ 0.01), and were more likely to have
CKD stage 2–4 at diagnosis (29 vs 15% in group 1; P¼ 0.03).
In a Cox regression model, the only variable significantly
associated with an unfavorable renal outcome was therapeu-
tic delay (P¼ 0.02; relative risk 1.7 (1.1–2.7) per year delay).
CKD stage 2–4 at initial presentation (P¼ 0.12; relative risk
3.7 (0.7–20.0)) was not significant.
DISCUSSION
Few studies have addressed the renal outcome of patients
with PH under conservative treatment. Our study is the first
to evaluate the outcome of renal function exclusively in
formally proven PH1 patients, with inclusion of all French
children. This is relevant as patients with PH2, and secondary
hyperoxaluria, can also reach ESRD, but the time at which
this occurs may differ from that of PH1.9,20,21
In this study, 7/27 children with PH1 deteriorated their
renal function after a median follow-up of 7.7 years, 5 of
whom required RRTafter a median time of 9.2 years. The last
GFR was below 60ml/min per 1.73m2 in eight children, five
of whom already had impaired GFR at diagnosis. The choice
of a cutoff GFR of 60ml/min per 1.73m2 for discrimination
was dictated by the notion that as renal function declines, so
does the excretion of oxalate, leading to further accumula-
tion. The threshold GFR below which degradation is
unavoidable was estimated to be between 40 and 50ml/min
per 1.73m2. Such a notion is linked to therapeutic strategies.
We, therefore, chose a GFR of 60 (CKD stage 2 or more) to
identify patients at low risk of further renal degradation.
Among the 15 patients with baseline GFR below 90, 8
improved their GFR, suggesting that a low GFR at diagnosis
does not necessarily represent a risk for developing ESRD.
This may be related to the presence of initial renal
Table 3 | Outcome of 27 PH1 patients on conservative treatment
Variable Total (n=27) Group 1 (n=20) Group 2 (n=7) P-value
Median follow-up, years (range) 8.7 (1.8–18.8) 6.7 (1.8–18.8) 9.6 (7.1–11.0) 0.14
Death, n (%) 1 (4) 1 (5) 0
CKD stage 2–4, n (%) (ESRD excluded) 6 (22) 3 (15) 3 (43)
ESRD, n (%) 4 (15) 0 4 (57)
Age at RRT, years (range) 16.2 (15.1–21.2)
Transplantation, n (%) 4 (14.8) 0 4 (57)
Age at transplantation, years (range) 18.3 (15.1–22.1)
Renal stone passage, mean±s.e. (range) 2.1±0.5 (0–7) 1.7±0.5 (0–7) 3.3±1.2 (0–7) 0.17
ESWL or open surgery, mean±s.e. (range) 1.5±0.4 (0–8) 1.2±0.4 (0–6) 2.6±1.1 (0–8) 0.07
Radiological evolution, n (%) 0.78
Stabilization or improvement 21 (78) 16 (80) 5 (72)
Degradation 3 (11) 2 (10) 1 (14)
Unavailable 3 (11) 2 (10) 1 (14)
GFR evolution
Initial GFR (ml/min per 1.73m2) 74 (29–141) 85 (29–141) 69 (48–100) 0.33
Initial GFR (RRT excluded) 85 (29–141) 85 (29–141) 87 (74–100)
Final GFR (ml/min per 1.73m2) 105 (7–195) 118.5 (51–195) 16 (7–57)
Final GFR (RRT excluded) 114 (40–195) 118.5 (29–195) 48.5 (40, 57)
DGFR (ml/min per 1.73m2) 11 (86, +124) 17.5 (16, +124) 43 (86,35)
DGFR (RRT excluded) 12 (40, +124) 17.5 (16, +124) 40 (43, 35)
CKD, chronic kidney disease; ESRD, end-stage renal disease; ESWL, extracorporal shock wave lithotripsy; GFR, glomerular filtration rate; PH1, primary hyperoxaluria type 1; RRT,
renal replacement therapy.
Results are given as median except when otherwise specified.
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Figure 1 | Evolution of glomerular filtration rate in 27 children
under conservative treatment from first to last follow-up.
Children belonging to group 1 are represented with solid lines,
group 2 children, with a decline in renal function by more than
20ml/min per 1.73m2, are represented with dotted lines. Children
who were under 1 year of age at diagnosis are represented with
filled triangles, children between 1 and 2 years of age with open
triangles, and others with a rectangle. GFR, glomerular filtration
rate, as estimated by the Schwartz formula.
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obstruction and reversible renal impairment in some and to
natural maturation of renal function in children below 2
years of age at diagnosis (5/7 with initial GFRo90). Milliner
et al.10 reported 3/9 PH1 patients with ESRD after 9 years of
follow-up and a decline in GFR of 1.4ml/min per 1.73m2 per
year and later reported 4/12 patients with ESRD after 10 years
of mean follow-up.20 Lieske et al.9 reported 15/74 PH
patients (PH1 and -2 and unclassified hyperoxaluria) with
ESRD after 9 years of median follow-up. For van Woerden
et al.,22 8/30 patients, adults, and children developed CKD
during a median follow-up of 7.7 years, 5 of whom reaching
ESRD. Among the 15 screened for diagnosis, 4 developed
CKD stage 2 or more. In our study, the median time interval
between initiation of conservative measures and stage 3 CKD
was 4.1 years and chronological age 13.1 years, whereas it was
at a chronological age of 30 years (22.2–37.7) in the study by
van Woerden et al.22 No publication has focused on renal
survival in children, discounting those adults with late onset
of PH. After 10 years of follow-up, the cumulative incidence
of CKD stage 2 or more was 54% in this study. For Milliner
et al.,10 cumulative incidences of ESRD at 5, 10, and 15 years
of treatment were 4, 11, and 25%, respectively, vs 0 and 20%
RRT at 5 and 10 years, respectively, in our study. However,
Milliner’s study included all types of PH, thus it probably
underestimates ESRD in PH1 patients. For Kopp et al.,23
ESRD was reached in 20% of PH patients by 15 years of age.
Median time without ESRD in PH1 was 33 years for Lieske
et al.,9 with an actuarial renal survival for all PH of 97, 91,
and 64% at 10, 20, and 30 years, respectively. In this study,
survival-free from RRT was 100 and 73% at 15 and 18 years
of age, respectively, with six patients having reached
adulthood (18 years). The outcome in our study is similar
to that of Lieske9 and Kopp.23 The patients in this study
benefited from an early treatment, thus improving outcome.
Improvement of renal function has been shown even when
renal insufficiency was already present at the time of
diagnosis.22,23 The age at onset of symptoms in our study
was lower than that in other studies: median of 2.4 vs 5.5
years for Lieske et al.9 and 6 years for van Woerden et al.,22 as
these studies included adult and pediatric patients, as well as
PH1, -2, and atypical PH for Lieske et al. The younger
patients in our study belonged to group 1 as they were
diagnosed by family screening; however, all patients pre-
sented with symptoms before 8 years of age, and only 4/27
after 5 years of age. The diagnosis was also made earlier, with
a median age at diagnosis of 4 years, compared with 7 years
for van Woerden et al.22 and 15 years for Lieske et al.9 The
therapeutic delay in our study was therefore shorter (0.6
years), though over 8 years in four, three of whom degraded
their renal function later on. The delay to diagnosis is often
long in PH, with a reported mean time of 5 years for Lieske
et al.9 and a median time of 8 years for Kopp et al.10,23
In our study, only the therapeutic delay was associated
with a degradation of renal function. This factor had not
been previously shown to be associated with an unfavorable
outcome,22 and suggests the importance of irreversible renal
damage, even after optimal treatment has been started. This
stresses the crucial role of early diagnosis and management of
PH. Conversely, the presence of nephrocalcinosis and
pyridoxine unresponsiveness was not found to be associated
with deterioration of renal function. This might be explained
by the small number of patients with nephrocalcinosis. No
conclusion can be drawn about B6 response, as formal testing
was not available for all patients.
The end point of this study was the outcome of PH1
children, a population more homogenous than a mixed adult
and children population. Six children had a diagnosis made
as part of a family screening but only three of them were
symptom-free at that time as nephrocalcinosis was already
present in four. Precocious silent renal lesions have been
reported by others.9,22,23 Of the three patients asymptomatic
at diagnosis, only one remained symptom-free as the others
formed renal stone during follow-up that disappeared after
readjustment of treatment to body weight. This points out
the continuous benefits of treatment, whatever the stage of
the disease may be. There was no advantage to enteral as
opposed to oral hydration, as the critical factor is the volume
and not the way through which the fluid is taken. Of the four
children who reached ESRD, one had a stable renal function
with GFR around 50ml/min per 1.73m2 for 7 years and
suddenly degraded her renal function within 1 month until
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she reached ESRD (Figure 2). This occurred after a complete
lapse in compliance, which is known to be a major
determinant. Lapses in compliance led to the apparition of
renal stones in two patients in a matter of months after the
end of this study. The transition to adult care is a sensitive
one and adolescents are here also particularly at risk.
The frequency of the G170R mutation was only 16% here,
although it is reported to be the most frequent mutation
amounting to a third of all mutations.24,25 However, the
I244T represented 26%, which reflects on the ethnicity of our
population, as it is predominant in Mediterranean coun-
tries.26,27 No phenotype–genotype correlation could be
established in our study.
This study was conducted retrospectively in a limited
number of patients, which was due to the low prevalence of
the disease, especially in the pediatric age group. The
management of patients was rather homogenous and
followed international standards. Despite the crucial role of
compliance, it was not taken into account as it had not been
evaluated in all patients. The GFR was estimated using the
Schwartz formula as only a subset of patients were evaluated
with inulin clearance. However, our conclusions are based on
GFR changes and not on GFR absolute values.
In summary, an early and aggressive treatment may
preserve renal function in compliant children with PH1. A
favorable course results from a delicate balance between
the natural history of the disease and its management.
Conservative treatment must be adapted to body weight
to fit child’s growth. The presence of silent symptoms
in patients who are screened for diagnosis is a reminder
of the necessity of an early diagnosis. A longer follow-up
of such patients would enable us to determine if the stability
of GFR that we observed can delay the onset of ESRD.
New treatments are now being developed, which may help
stabilize or slow down the decline in renal function in
addition to standard conservative treatment and further delay
ERSD.
MATERIALS AND METHODS
Study design
We conducted a multicenter retrospective cohort study. All children
aged less than 15 years followed in a French-speaking center for at
least 1 year, with an enzymatically or genetically proven PH1
between 1986 and 2006, were identified from the database of the
only reference center for enzymatic or genetic diagnosis of PH1 in
France (Laboratoire de Biologie Est, Hospices Civils de Lyon). We
then contacted all the centers where these children were followed to
collect clinical and biological follow-up data.
Population and data collection
PH1 was defined on the basis of the following criteria: AGT activity
below 50% on liver biopsy, or mutations in AGXT, or urinary
biochemistry in favor of PH1 in siblings of enzymatically or
genetically proven PH1 patients. Enzymatic studies and mutation
analysis were performed in the same laboratory. The age at diagnosis
was considered to be that of initiation of conservative treatment
even if enzymatic or genetic confirmation was performed later.
Clinical and laboratory information was collected on chart review.
Baseline characteristics such as gender, ethnic origin, family history
of nephrolithiasis or PH1, and consanguinity were recorded, as well
as clinical presentation, renal events, and their timing (stone
passage, nephrocalcinosis, dialysis, and transplantation). The
treatment delay was considered to be the time elapsed between the
first symptom and initiation of conservative treatment. Laboratory
data included plasma creatinine concentration, height and body
weight, AGXT mutations, and AGT enzymatic activity. Renal
insufficiency at diagnosis was defined as a GFRo90ml/min per
1.73m2 and was classified as transient or chronic if renal function
could not be restored 3 months after the initiation of treatment;
CKD was staged according to the Kidney Disease Outcome Quality
Initiative and Kidney Disease Improving Global Outcome
stages,28,29 and was defined as a GFRo60ml/min per 1.73m2
(stage 3).
Conservative treatment
Conservative treatment consisted of all children in hyperhydration
(X2–3 l/m2/day), administered orally or enterally (nasogastric or
gastric tube feeding), and urine alkalinization by sodium or
potassium citrate or sodium bicarbonate. Pyridoxine was adminis-
tered in B6-sensitive patients, but sensitivity was not universally
investigated in the absence of available guidelines. Details on
medical treatment were recorded (type of fluid intake, volume, type
and dose of urine alkalinization, and pyridoxine dose).
Statistical analysis
The main outcome was GFR estimated from Schwartz30 formula for
children under 18 years of age and with the Modification of Diet in
Renal Disease formula for adults.31 For end point analysis, patients
with ESRD and pre-emptive liver–kidney transplantation were
pooled together as RRTmay occur at a greater GFR in PH patients.
Patients were divided into two groups according to their renal
outcome: group 1 included children with stable renal function,
whereas group 2 had a decline in GFR over 20ml/min per 1.73m2
during the study period. Results were expressed as median and range
or mean±s.d. for continuous variables, and as percentage for
categorical variables. w2 or Student’s t-test was used for comparison
of normally distributed variables, and Wilcoxon test or Fisher’s exact
test was used for non-normally distributed variables. The probability
of remaining free from CKD or RRT was estimated using a time to
failure Kaplan–Meier method. A Cox proportional hazards model
was performed to determine factors associated with a decline in
GFR420ml/min per 1.73m2 during follow-up. All statistical
analyses were carried out with the use of SAS software (version
9.1; SAS Institute, Cary, NC, USA).
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